Recent news on Frovatriptan Succinate

Vernalis plc Announces Pricing and Reimbursement for Frova® in France  -  Apr 2, 2007
Oxfordshire Bioscience Network (press release),Frova® (frovatriptan succinate tablets) is a selective 5-HT 1B/1D receptor agonist approved as an acute oral treatment for migraine headache and its

Endo and Vernalis Plc Announce Three-Month Extension of PDUFA Date ...  -  Apr 2, 2007
Oxfordshire Bioscience Network (press release),Application (sNDA) for Frova® (frovatriptan succinate) 2.5 mg tablets for the expanded indication of short-term prevention of menstrual migraine (MM).

Vernalis plc Announces Pricing and Reimbursement for Frova in France  -  Mar 12, 2007
PharmaLive.com (press release),Frova(R) (frovatriptan succinate tablets) is a selective 5-HT1B/1D receptor agonist approved as an acute oral treatment for migraine headache and its

FDA Informs To Endo Pharma And Vernalis About Additional 3 Months ...  -  Mar 16, 2007
Trading Markets,...(frovatriptan succinate) 2.5 mg tablets for the expanded indication of short-term prevention of menstrual migraine (MM | charts | news | PowerRating).

Endo and Vernalis plc Announce Three-Month Extension of PDUFA Date ...  -  Mar 16, 2007
PharmaLive.com (press release),Application (sNDA) for Frova(R) (frovatriptan succinate) 2.5 mg tablets for the expanded indication of short-term prevention of menstrual migraine (MM).

Vernalis Plc Announces FDA Acceptance For Filing Of Frova(R) For ...  Sep 21, 2006
...the US Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for Frova(R) (frovatriptan succinate) 2.5 mg ... -Medical News Today

Vernalis Plc: Interim Results for the Six Months Ended 30 June ...  Sep 11, 2006
Parkinson's disease drug, Apokyn(R) (apomorphine hydrochloride injection), as well as co-promoting its migraine drug, Frova(R) (frovatriptan succinate) 2.5 mg ... -PR Newswire

Vernalis plc: Interim Results for the six months ended 30 June ...  Sep 13, 2006
Parkinson’s disease drug, Apokyn® (apomorphine hydrochloride injection), as well as co-promoting its migraine drug, Frova® (frovatriptan succinate) 2.5 mg ... -Oxfordshire Bioscience Network

Vernalis plc and Endo Pharmaceuticals Holdings Inc. Announce North ...  Aug 7, 2006
Endo�), today announced an agreement for Vernalis to license exclusive North American sales and marketing rights to Frova™ (frovatriptan succinate, 2.5mg ... -Biotechnology Investment Today

Endo Pharmaceuticals and Vernalis plc Announce the Filing of the ...  Jul 19, 2006
...that Endo has submitted to the US Food and Drug Administration (FDA) a supplemental New Drug Application (sNDA) for Frova® (frovatriptan succinate) 2.5 mg ... -Yahoo! News

Vernalis Submits New Drug Application For Frova >VNLS  Jul 20, 2006
...that Endo has submitted to the US Food and Drug Administration (FDA) a supplemental New Drug Application (sNDA) for Frova (frovatriptan succinate) 2.5 mg ... -Therapeutics Daily (subscription)



Vernalis plc to Ring the NASDAQ Closing Bell on May 18, 2006  May 14, 2006
...trading on NASDAQ in July 1992, is celebrating the positive outcome of the Company's second Phase III efficacy study of Frova® (frovatriptan succinate) 2.5 mg ... - Yahoo! News

Frova(R) Meets Primary Endpoint In Second Phase III Study For ...  May 10, 2006
...(Nasdaq: ENDP) today announced top-line data from the second Phase III efficacy study of Frova(R) (frovatriptan succinate) 2.5 mg tablets for the short-term ... - Medical News Today

Vernalis Gets Top-Line Data From Frova Phase III Study  May 8, 2006
Monday announced top-line data from the second Phase III efficacy study of Frova (frovatriptan succinate) 2.5 mg tablets for the short-term (six-days per month ... - Therapeutics Daily (subscription)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional